AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor

Abbott Laboratories: new opportunities from strategic split

The restructuring will allow each new business to develop specific strategies tailored to their distinct markets. This is particularly important for the branded pharmaceutical segment, which is forecast to see low growth over the next five years. Datamonitor expects steady growth from the new medical products company and lower risk for stockholders, itself a primary driver behind this event.

Published By Datamonitor

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor

Acambis: leading the pack on West Nile fever vaccine

Concern is rising in parts of the US that a West Nile fever outbreak could cause an epidemic worse than that experienced in 2004, due to a wet spring and diminishing immunity in the bird population. The increasing impact of the West Nile Virus since its arrival in the US in 2000 highlights the need for a preventative vaccine, with Acambis [ACM.L] leading the race to bring one to market.

Published By Datamonitor

Acute heart failure: 945,000 US cases in 2001

Published By Datamonitor

Acute respiratory distress syndrome: searching for effective therapies

Acute respiratory distress syndrome has an annual incidence of up to 75 cases per 100,000 in the US. The condition remains very difficult to treat with a mortality rate between 30% and 60%. Although much research into ARDS has been carried out, the lack of a standard definition for the condition has made trial results unclear, so what hope is there of a treatment breakthrough in the near future?

Published By Datamonitor

ADHD: 7,000 fewer UK diagnoses by 2010

Published By Datamonitor

ADHD: NICE ruling for Ritalin, but will it boost sales?

Published By Datamonitor

All out for OTC

Published By Datamonitor